Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune® platform candidate targets MUC1-positive solid tumors U.S. Patent #12, ...
Researcher suggests compounds secreted by high-risk MSCs that are detectable in the bloodstream could act as biomarkers for ...
Promising preliminary Phase 2b (ASCEND) pancreatic cancer data (Cohort A) reported with Cohort B data anticipated in the coming monthsEnrollment ...
Given these findings, a diagnosis of HAC of the colon with metastasis to a mesenteric lymph node was made. We present the case of a young woman with hepatoid adenocarcinoma (HAC) of the colon, which ...
A personalized vaccine demonstrated the potential to induce long-lasting immune response among people with advanced kidney ...
Q4 2024 Earnings Call Transcript February 28, 2025 Fulgent Genetics, Inc. beats earnings expectations. Reported EPS is $0.04, ...
Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ETCompany ParticipantsMike Brophy - Chief Financial ...
The NCI will lead the trial of the firm's Versamune MUC1 immunotherapy and its antibody-drug conjugate PDS01ADC.
Tumor growing and spreading over healthy tissue causing inflammation and metastasis ... gut intestine, Colon polyp removal, colonic polyps search, Polypectomy, intestinal carcinoma, bowel neoplasia, ...